^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + brivanib alaninate (BMS-582664) (VEGFR-2 inhibitor, FGFR1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
...for the treatment of advanced CRC include sunitinib plus FOLFIRI, cetuximab plus brivanib, erlotinib plus bevacizumab, cediranib plus FOLFOX/CAPEOX, and atezolizumab plus cobimetinib. These regimens are not recommended for the treatment of patients with CRC.
